Tango Therapeutics, Inc. (TNGX)
NASDAQ: TNGX · Real-Time Price · USD
23.78
+0.41 (1.75%)
Sep 11, 2026, 4:00 PM EDT - Market closed
Tango Therapeutics Revenue
Tango Therapeutics had revenue of $53.81M in the twelve months ending June 30, 2026, up 121.47% year-over-year. In the year 2025, Tango Therapeutics had annual revenue of $62.38M with 48.29% growth.
Revenue (ttm)
$53.81M
Revenue Growth
+121.47%
P/S Ratio
74.51
Revenue / Employee
$392,781
Employees
137
Market Cap
4.01B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 62.38M | 20.32M | 48.29% |
| Dec 31, 2024 | 42.07M | 5.54M | 15.17% |
| Dec 31, 2023 | 36.53M | 11.67M | 46.93% |
| Dec 31, 2022 | 24.86M | -12.18M | -32.89% |
| Dec 31, 2021 | 37.04M | 29.39M | 383.83% |
| Dec 31, 2020 | 7.66M | -16.99M | -68.94% |
| Dec 31, 2019 | 24.65M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Legend Biotech | 1.27B |
| Telix Pharmaceuticals | 890.79M |
| Tarsus Pharmaceuticals | 606.33M |
| Iovance Biotherapeutics | 324.97M |
| IDEAYA Biosciences | 234.13M |
| Arcus Biosciences | 117.00M |
| Relay Therapeutics | 10.35M |
TNGX News
- 3 days ago - Tango Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 8 days ago - Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 11 days ago - Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference - GlobeNewsWire
- 25 days ago - Tango Therapeutics price target raised to $68 from $66 at H.C. Wainwright - TheFly
- 26 days ago - Tango Therapeutics price target raised to $35 from $32 at Guggenheim - TheFly
- 4 weeks ago - Tango Therapeutics reports Q2 EPS (37c), consensus (32c) - TheFly
- 4 weeks ago - Tango Therapeutics Quarterly report: Q2 2026 - Filings
- 4 weeks ago - Tango Therapeutics Earnings release: Q2 2026 - Filings